Publications & Resources

With the assistance of Aboriginal and Torres Strait Islander people, Cancer Australia has compiled answers to Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer. These FAQs provide information for members of the healthcare team, including Aboriginal and Torres Strait Islander Health Workers, Health Practitioners, Hospital Liaison Officers. The FAQs are based on information and evidence currently available in Australia and internationally, and will be updated as new information emerges.

With the assistance of Aboriginal and Torres Strait Islander people, Cancer Australia has compiled answers to Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people who have been affected by cancer. The answers to these FAQs are based on information and evidence currently available in Australia and internationally, and will be updated as new information emerges.

These Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer were compiled by Cancer Australia with input from cancer clinicians and people affected by cancer. The answers to these FAQs are based on information and evidence currently available in Australia and internationally. These FAQs will be updated as new information emerges.

This report provides findings from an analysis of Medicare Benefits Schedule (MBS) data for the months January 2020 to September 2020 to understand where changes in the number of cancer-related services have occurred, and the types of services affected, during the COVID-19 pandemic. For relevant procedure groups, jurisdictional breakdowns of monthly services are provided. These analyses focus on changes in cancer-related diagnostic and treatment procedures for breast, colorectal, lung, prostate and skin cancers.

The report on the Lung Cancer Screening enquiry outlines the findings of the enquiry, including the national and international evidence on lung cancer screening, the best design for a screening program within the Australian health policy context and the mechanics of how a lung cancer screening program could be effectively delivered in Australia.

This report provides findings from an analysis of Medicare Benefits Schedule (MBS) data for the months January 2020 to June 2020 to understand where changes in the number of cancer-related services have occurred, and the types of services affected during the COVID-19 pandemic. These analyses focus on changes in cancer-related diagnostic and treatment procedures for lung and prostate cancers.

This information is for women who have been treated for early breast cancer or ductal carcinoma in situ (DCIS) and their carers. It provides information about shared follow-up and survivorship care, including the benefits of shared care and who is involved.

Cancer Australia's Annual Report for the 2019-2020 reporting period

This document contains the 200 recommendations and practice points that comprise the Guidance for the management of early breast cancer. The Guidance has been developed as an essential resource for health professionals involved in the management of women and men with breast cancer. It updates and replaces in full or in part Cancer Australia’s 2001 Clinical Practice Gguidelines for the management of breast cancer in women and various subsequent topic-specific updates. This Guidance has been developed to meet the need for comprehensive, up-to-date, evidence-based guidance that encompasses management of early breast cancer from the point of diagnosis. The Guidance is also presented in a user-friendly, accessible format on a Cancer Australia featured site at www.guidancebreastcancer.gov.au.

This reportdescribes the approach taken to develop the Guidance for the Managment of the early breast cancer.